Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Personnel Growth Looks To Have Plateaued For Drugs Program

Executive Summary

Only a handful of new FTEs are requested in President Obama’s FY 2016 budget request for human drugs activities, suggesting that GDUFA and other related programs may have reached their critical mass of employees for now.

You may also be interested in...



FDA Talent Hunt: Better To Recruit From Academia Than Industry?

CDER Oncology office head Richard Pazdur says making FDA more academic could help with retention. In addition to having fewer staff than needed to complete its work, FDA’s hiring problem makes it difficult for the agency to stay abreast of new scientific discoveries and technology.

FDA Talent Hunt: Better To Recruit From Academia Than Industry?

CDER Oncology office head Richard Pazdur says making FDA more academic could help with retention. In addition to fewer staff than needed to complete its work, FDA’s hiring problem makes it more difficult for the agency to stay abreast of new scientific discoveries and technology.

FDA Talent Hunt: Better To Recruit From Academia Than Industry?

CDER Oncology office head Richard Pazdur says making FDA more academic could help with retention. In addition to fewer staff than needed to complete its work, FDA’s hiring problem makes it more difficult for the agency to stay abreast of new scientific discoveries and technology.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS056658

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel